<DOC>
	<DOCNO>NCT00878670</DOCNO>
	<brief_summary>In study investigate patient atopic dermatitis respond EPOGAM treatment , show significant increase dihomo-gamma-linolic acid blood .</brief_summary>
	<brief_title>Investigation Efficacy Safety EPOGAM</brief_title>
	<detailed_description>Patients atopic dermatitis receive EPOGAM 1000 12 week . Clinical symptom disease assess use SCORAD score . Dihomo-gamma-linolic acid level blood measure GC-MS .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Neurodermatitis</mesh_term>
	<mesh_term>Efamol</mesh_term>
	<criteria>atopic dermatitis since least 2 month ( criterion Hanifin Rajka , 1980 ) men woman age 2 45 year woman childbearing age use contraception inform consent patient parent psychiatric disorder abuse drug alcohol chronic dermatosis glaucoma , cataract ocular herpes simplex Immune deficiency Immunological diseases clinical relevant change laboratory parameter congenital disease scabies , infection dermathophytae , HIVassociated dermatosis malignant diseases metabolic disease parasites patient enrolled study progredient , systemic disease pregnancy lactation severe internistic disease organ transplantation medical history hypersensitivity ingredient study medication</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>